Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.

Stocks | Futures | Watchlist | More
or

Biotech Vaneck ETF (BBH)

Biotech Vaneck ETF (BBH)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fund Basics

See More
  • Fund Family Van Eck Associates
  • Assets Under Management 563,863,200
  • Shares Outstanding, K 2,847
  • 60-Month Beta 0.90
Trade BBH with:
  • Price/Earnings ttm 29.78
  • Annual Dividend & Yield 0.61 (0.31%)
  • Most Recent Dividend 0.608 on 12/21/20
  • Management Fee 0.35%
  • Sectors:

    ETFs - Biotech

Options Overview

Details
  • Implied Volatility 17.91%
  • Historical Volatility 19.68%
  • IV Percentile 0%
  • IV Rank 2.05%
  • IV High 34.87% on 10/30/20
  • IV Low 17.55% on 06/18/21
  • Put/Call Vol Ratio 0.00
  • Today's Volume 40
  • Volume Avg (30-Day) 182
  • Put/Call OI Ratio 0.38
  • Today's Open Interest 458
  • Open Int (30-Day) 661

Price Performance

See More
Period Period Low Period High Performance
1-Month
180.99 +9.67%
on 05/27/21
201.15 -1.32%
on 06/10/21
+16.77 (+9.23%)
since 05/21/21
3-Month
168.43 +17.85%
on 03/25/21
201.15 -1.32%
on 06/10/21
+22.15 (+12.56%)
since 03/23/21
52-Week
150.52 +31.87%
on 10/30/20
201.15 -1.32%
on 06/10/21
+34.26 (+20.86%)
since 06/23/20

Most Recent Stories

More News
Biogen's Alzheimer's Drug Approval Puts Biotech ETFs in Spotlight

The FDA's approval of the first new drug to treat Alzheimer's disease in about 20 years has attracted investors' attention toward the biotech sector while sparking new controversies.

BIIB : 367.28 (-1.90%)
IBB : 160.46 (-0.28%)
XBI : 133.03 (-0.49%)
BBH : 198.23 (+0.04%)
FBT : 172.69 (-0.45%)
BTEC : 59.80 (+0.82%)
ETFs to Win as Moderna Seeks COVID-19 Vaccine Nod for Teens

Moderna (MRNA) is once again in the spotlight with an impressive update relating to mRNA-1273.

MRNA : 216.24 (-2.31%)
IBB : 160.46 (-0.28%)
BBH : 198.23 (+0.04%)
IDNA : 49.10 (+0.04%)
GERM : 38.40 (-0.64%)
Top COVID-19 Vaccine Stories of May Put Biotech ETFs in Focus

Let's take a look at some top coronavirus vaccine stories of May and the possible impact they can have on biotech ETFs.

SNY : 52.26 (-0.08%)
AZN : 58.16 (+0.47%)
PFE : 39.41 (-0.50%)
MRNA : 216.24 (-2.31%)
IBB : 160.46 (-0.28%)
XBI : 133.03 (-0.49%)
BBH : 198.23 (+0.04%)
FBT : 172.69 (-0.45%)
BTEC : 59.80 (+0.82%)
BNTX : 232.09 (-1.86%)
CVAC : 55.82 (-3.92%)
Biotech ETFs to Suffer as US Backs IP Waiver for COVID-19 Vaccines

The Biden administration recently informed about supporting the waiver of intellectual property protections for COVID-19 vaccines that has been proposed by South Africa and India.

JNJ : 162.85 (-0.47%)
AZN : 58.16 (+0.47%)
PFE : 39.41 (-0.50%)
MRNA : 216.24 (-2.31%)
IBB : 160.46 (-0.28%)
XBI : 133.03 (-0.49%)
BBH : 198.23 (+0.04%)
FBT : 172.69 (-0.45%)
BTEC : 59.80 (+0.82%)
How Will Biotech ETFs React to These Q1 Earnings Releases?

Let's take a look at some big biotechnological earnings releases to see if these will impact ETFs exposed to the space.

BIIB : 367.28 (-1.90%)
ALXN : 180.11 (+0.27%)
GILD : 66.71 (-0.51%)
AMGN : 238.66 (-0.52%)
IBB : 160.46 (-0.28%)
XBI : 133.03 (-0.49%)
BBH : 198.23 (+0.04%)
Top COVID-19 Vaccine Stories of April Put Biotech ETFs in Focus

Let's take a look at some top coronavirus vaccine stories of April and the possible impact they can have on biotech ETFs.

JNJ : 162.85 (-0.47%)
AZN : 58.16 (+0.47%)
NVAX : 196.48 (+1.09%)
IBB : 160.46 (-0.28%)
XBI : 133.03 (-0.49%)
BBH : 198.23 (+0.04%)
FBT : 172.69 (-0.45%)
BTEC : 59.80 (+0.82%)
OCGN : 7.33 (-1.08%)
IBRX : 14.02 (+2.64%)
Novavax Vaccine to Get U.S. Approval? ETFs to Benefit

Novavax (NVAX) is reportedly set to receive the fourth authorization for COVID-19 vaccine in the United States.

JNJ : 162.85 (-0.47%)
AZN : 58.16 (+0.47%)
NVAX : 196.48 (+1.09%)
IBB : 160.46 (-0.28%)
XBI : 133.03 (-0.49%)
BBH : 198.23 (+0.04%)
VIRS : 31.28 (+0.22%)
BUZZ : 26.08 (+0.95%)
GERM : 38.40 (-0.64%)
Top COVID-19 Vaccine Stories of March Put Biotech ETFs in Focus

Investors are closely tracking the progress in coronavirus vaccine development amid the pandemic's renewed resurgence with multiple mutants.

AZN : 58.16 (+0.47%)
PFE : 39.41 (-0.50%)
MRNA : 216.24 (-2.31%)
NVAX : 196.48 (+1.09%)
IBB : 160.46 (-0.28%)
XBI : 133.03 (-0.49%)
BBH : 198.23 (+0.04%)
FBT : 172.69 (-0.45%)
BTEC : 59.80 (+0.82%)
BNTX : 232.09 (-1.86%)
Moderna ETFs to Gain on Positive 'Real-World' Study Data

Positive coronavirus vaccine progress by Moderna (MRNA) grabs investors' attention.

PFE : 39.41 (-0.50%)
MRNA : 216.24 (-2.31%)
IBB : 160.46 (-0.28%)
BBH : 198.23 (+0.04%)
BTEC : 59.80 (+0.82%)
GERM : 38.40 (-0.64%)
Will ETFs Gain on AstraZeneca's Latest Covid-19 Vaccine Update?

Investors are closely tracking the progress in coronavirus vaccine development amid the pandemic's renewed resurgence thanks to multiple mutants.

AZN : 58.16 (+0.47%)
MRNA : 216.24 (-2.31%)
NVAX : 196.48 (+1.09%)
IBB : 160.46 (-0.28%)
CNCR : 31.00 (+0.89%)
XBI : 133.03 (-0.49%)
PPH : 72.65 (-0.32%)
BBH : 198.23 (+0.04%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Buy with a Strongest short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Fund Summary

The VanEck Vectors Biotech ETF seeks to replicate as closely as possible, before fees and expenses, the price and yield performance of the MVIS US Listed Biotech 25 Index, which is intended to track the overall performance of companies involved in the development and production, marketing and sales of...

See More

Key Turning Points

3rd Resistance Point 201.16
2nd Resistance Point 199.66
1st Resistance Point 198.91
Last Price 198.23
1st Support Level 196.66
2nd Support Level 195.16
3rd Support Level 194.41

See More

52-Week High 201.15
Last Price 198.23
Fibonacci 61.8% 181.81
Fibonacci 50% 175.83
Fibonacci 38.2% 169.86
52-Week Low 150.52

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar